Active Studies


Patient Identification Centre (PIC)


Shore Medical is a recognised Participant Identification Centre (PIC) for Commercial Research Studies and as such work with Participating Organisations including The Adams Practice.

We are currently acting as a PIC site for the ZEUS study which is looking at the effects of ziltivekimab versus placebo on cardiovascular outcomes for patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.


 Shore Medical are soon to be working with uMed helping with recruiting to the Access-PD (Parkinson’s) and Adams (MS) studies. These are similar to the Harmonie study in which we were also involved with recruitment.

We are not directly involved with the running of these studies therefore any queries should be directed to the uMed Research Nursing team on 0207 861 4428.


Shore Medical is taking part in the ATTACK trial with support from the nurses at the Clinical Research Network. This is investigating the use of aspirin to target arterial events in chronic kidney disease. ATTACK is a large-scale academic study, being led by the University of Southampton, to see whether or not patients with chronic kidney disease should take aspirin daily to prevent a first heart attack or stroke. It is recruiting patients from GP practices across the UK and looks to invite 198,000 patients.

ATTACK Trial | University of Southampton

SHIP Trial

Shore Medical is taking part in the Studying Hypertension Plus (SHIP) Qualitative study which will explore how well a new system called Hypertension Plus (HTN+) to help health care professionals (HCPs) and people with hypertension to manage their condition together works in practice.  The HTN+ system involves people with hypertension (or their caregivers) measuring their blood pressure at home, with input from an HCP or specialist when needed.  We will ask HCPs in our study if we can make a recording of their conversations with patients about using (or not using) HTN+.  The study will start in September 2021 and end in December 2022.


Amitriptyline for the prevention of post-herpetic neuralgia. Shore medical is taking part in the ATHENA study :  Can taking amitriptyline tablets as soon as possible after the rash of shingles appears stop long term pain?

The study is looking at patients over the age of 50 who have been diagnosed by their GP with shingles. Participants will be asked to take tablets nightly for 10 weeks:  half will be given amitriptyline and the other half will get placebo (or “dummy”) tablets. Questionnaires will then be used to follow up outcomes over the subsequent 12 months.


Determining the Effectiveness of a Fractional Exhaled Nitric Oxide (FeNO) in guided asthma management intervention. This study uses an intervention tool for doctors and nurses in GP surgeries to help them use FeNO to target and adjust asthma treatments more effectively.

Do you have asthma?  Are you aged 12 or above and due for your annual asthma review?  If so you might be eligible for a new asthma research trial we are running to investigate whether a simple, easy breath test called FeNO can improve asthma care.  For more information please click here.  If you would like to discuss this more please contact us at

Clinical Practice Research Datalink (CPRD)

Shore Medical is signed up to CPRD, this is a real-world research service supporting retrospective public health and clinical studies. CPRD is jointly sponsored by the Medicines and Healthcare products Regulatory Agency and National Institute for Health and Research, as part of the Department of Health and Social Care. CPRD collects anonymised patient data from a network of GP practices across the UK. For more than 30 years, research using CPRD data and services has informed clinical guidance and best practice, resulting in over 2,800 peer-reviewed publications investigating drug safety, use of medicines, effectiveness of health policy, health care delivery and disease risk factors. CPRD only receives and supplies anonymised patient data and complies with robust ethics, governance and security regulatory frameworks.